Literature DB >> 24032663

Decontamination of prions in a plasma product manufacturing environment.

Anne Bellon1, Emmanuel Comoy, Steve Simoneau, Sandrine Mornac, Capucine Dehen, Audrey Perrin, Aude Arzel, Samuel Arrabal, Henry Baron, Hubert Laude, Bruno You, Jean-Philippe Deslys, Benoit Flan.   

Abstract

BACKGROUND: The high resistance of prions to inactivating treatments requires the proper management of decontaminating procedures of equipment in contact with materials of human or animal origin destined for medical purposes. Sodium hydroxide (NaOH) is widely used today for this purpose as it inactivates a wide variety of pathogens including prions. STUDY DESIGN AND METHODS: Several NaOH treatments were tested on prions bound to either stainless steel or chromatographic resins in industrial conditions with multiple prion strains.
RESULTS: Data show a strong correlation between inactivation results obtained by immunochemical detection of the prion protein and those obtained with infectivity assays and establish effective inactivation treatments for prions bound to stainless steel or chromatographic resins (ion exchange and affinity), including treatments with lower NaOH concentrations. Furthermore, no obvious strain-specific behavior difference was observed between experimental models.
CONCLUSION: The results generated by these investigations show that industrial NaOH decontamination regimens (in combination with the NaCl elution in the case of the chromatography process) attain substantial prion inactivation and/or removal between batches, thus providing added assurance to the biologic safety of the final plasma-derived medicinal products.
© 2013 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24032663     DOI: 10.1111/trf.12381

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  4 in total

1.  Addition of exogenous α-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α-synuclein to Lewy body and Lewy neurite-like aggregates.

Authors:  Laura A Volpicelli-Daley; Kelvin C Luk; Virginia M-Y Lee
Journal:  Nat Protoc       Date:  2014-08-14       Impact factor: 13.491

2.  Interventions to reduce the risk of surgically transmitted Creutzfeldt-Jakob disease: a cost-effective modelling review.

Authors:  Matt Stevenson; Lesley Uttley; Jeremy E Oakley; Christopher Carroll; Stephen E Chick; Ruth Wong
Journal:  Health Technol Assess       Date:  2020-02       Impact factor: 4.014

3.  Biological Safety of a Highly Purified 10% Liquid Intravenous Immunoglobulin Preparation from Human Plasma.

Authors:  Caroline Goussen; Steve Simoneau; Soline Bérend; Christine Jehan-Kimmel; Anne Bellon; Céline Ducloux; Bruno You; Philippe Paolantonacci; Monique Ollivier; Ludovic Burlot; Sami Chtourou; Benoît Flan
Journal:  BioDrugs       Date:  2017-06       Impact factor: 5.807

Review 4.  Renewed assessment of the risk of emergent advanced cell therapies to transmit neuroproteinopathies.

Authors:  Paul A De Sousa; Diane Ritchie; Alison Green; Siddharthan Chandran; Richard Knight; Mark W Head
Journal:  Acta Neuropathol       Date:  2018-11-27       Impact factor: 17.088

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.